Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

A Study to Investigate the Effect of a Meal At 6pm the Day Before the Colonoscopy on the Bowel Cleansing with Plenvu

NCT06651398 · tracked via the Priya Life Science Belgium tracker
Phase
Not applicable
Started
2023-02-14
Last updated
2024-10-21

Condition(s) studied

Bowel PreparationBowel Preparation for ColonoscopyBowel Cleansing for ColonoscopyHealthy

Investigational drug(s) / intervention(s)

Lenient diet

Lenient diet: The interventional goup receives the lenient diet instructions and will eat a light meal until 18h on the day before the colonoscopy. The first dose of Plenvu will be started at 20h. All the other bowel preparation instructions will be the same as in the control group.

Study summary

Bowel cleansing prior to colonoscopy is crucial to be able to perform a high-quality examination. Therefore maximum efforts are made to achieve optimal bowel cleansing including diet restriction and refraining from day-before dinner. However, the effect of this interdiction is currently not clear. On the other hand, patient compliance and experience with the entire procedure is important, especially for follow-up colonoscopies. Strict diets may interfere with this as an additional burden on the patient. In this study we want to assess whether a more lenient diet influences the quality of bowel preparation and whether it improves patient's experience.

Eligibility

Sex
ALL
Min age
40 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patient referred for diagnostic colonoscopy * Age between 40 and 85 years old * Ability of normal oral ingestion * Able to give informed consent by the patient or the legal representative Exclusion Criteria: * Participant has a history of (partial) colectomy, excluding appendectomy * Inability of oral ingestion * Chronic severe constipation, defined as the need for daily laxative use of any kind or the need to use laxatives to obtain defaecation. * Uncontrolled coagulopathy * Pregnancy * Premenopausal women not adhering to any contraceptive method * Inflammatory bowel disease * Lynch syndrome * Familial adenomatosis polyposis syndrome * Serrated polyposis syndrome * hypersensitivity to the active substances of PLENVU as listed in the SmPC section 6.1 * gastrointestinal obstruction or perforation * ileus * gastric emptying disorders (e.g. gastroparesis, gastric retention, etc.) * phenylketonuria (due to the presence of aspartame in PLENVU) * glucose-6-phosphate dehydrogenase deficiency (due to the presence of ascorbate in PLENVU) * toxic megacolon * Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol * Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial

Primary outcome measure(s)

  • Number of patients with an adequate bowel preparation (BBPS ≥6, and no segmental subscore ≤1) — Max 12 weeks

Trial sites (1)

FacilityCityRegionStatus
UZ Leuven Leuven Vlaams-Brabant
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06651398 on ClinicalTrials.gov ↗ ← All trials in Belgium